Report from Annual General Meeting in SyntheticMR AB (publ)
The Annual General Meeting (AGM) of SyntheticMR AB (publ) was held on May 21, 2024, whereby the meeting resolved in accordance with the Nomination Committee and Board's proposed resolutions. The full resolutions are stated in the notice of the meeting.
The following resolutions were made at the AGM:
The AGM resolved to approve the Board's proposal that no dividend will be paid. The remaining capitalized funds of SEK 91,016,542 including the share premium reserve and retained earnings, are transferred in new accounts.
The AGM resolved to grant the Board of directors and CEO discharge.
The AGM decided that the Board should consist of 5 ordinary members and no deputies. The AGM resolved on the new election of Board members Johanna Fälting and Gisli Hennermark, the re-election on Board members Ann-Christine Sundell, Jan Bertus Marten (Marcel) Warntjes, and Staffan Persson. Further, the AGM decided to elect Staffan Persson as the Chairman of the Board.
The AGM resolved that a Nomination Committee should be appointed by the Annual General Meeting instructing the Chairman of the Board to contact the three largest shareholders (hereby both direct registered shareholders and nominee-registered shareholders) in accordance with Euroclear Sweden AB's printout of the share register as of September 30, 2024.
The AGM decided in accordance with the resolution on changes to Incentive Program TO 3
For further details regarding the resolutions set out above please refer to the notice and the complete proposals available at the Company's website, www.syntheticmr.com.
For further information, please contact:
Ulrik Harrysson, CEO
+46 70 529 29 87
ulrik.harrysson@syntheticmr.com
Johanna Norén, CFO och Head of Investor Relations
+46 70 619 21 00
.
SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from a single 5-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative data on the brain. SyMRI MSK provides multiple contrast images and quantitative data for knee and spine anatomies. SyMRI NEURO is CE-marked and FDA 510(k) cleared and SyMRI MSK is CE-marked. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden. For more information, visit www.syntheticmr.com.